---
title: "Understanding the Market | LUYE PHARMA fell nearly 15% after earnings, with full-year net profit down 11% and tumor product sales decreasing by 1.8%"
description: "LUYE PHARMA fell nearly 15% after its earnings report, as of the time of publication, it dropped 14.11%, trading at HKD 2.13, with a transaction volume of HKD 274 million. In terms of news, LUYE PHARM"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/233825281.md"
published_at: "2025-03-31T06:20:04.000Z"
---

# Understanding the Market | LUYE PHARMA fell nearly 15% after earnings, with full-year net profit down 11% and tumor product sales decreasing by 1.8%

> LUYE PHARMA fell nearly 15% after its earnings report, as of the time of publication, it dropped 14.11%, trading at HKD 2.13, with a transaction volume of HKD 274 million. In terms of news, LUYE PHARMA released its annual performance report, with revenue of RMB 6.061 billion, a year-on-year decrease of 1.33%; profit attributable to shareholders was RMB 472 million, a year-on-year decrease of 11.4%; basic earnings per share were 12.54 cents. No final dividend was declared. During the reporting period, the sales of products in the central nervous system treatment field decreased by 4.8%, reaching RMB 1.613 billion. Sales of products in the oncology treatment field decreased by 1.8%, reaching RMB 2.085 billion. Sales of products in the cardiovascular system treatment field decreased by 1.6%, reaching RMB 1.660 billion. Sales of products in the metabolic treatment field decreased by 13.7%, reaching RMB 389 million

According to Zhitong Finance APP, LUYE PHARMA (02186) fell nearly 15% after its earnings report, as of the time of writing, it is down 14.11%, trading at HKD 2.13, with a transaction volume of HKD 274 million.

In terms of news, LUYE PHARMA released its annual performance report, with revenue of RMB 6.061 billion, a year-on-year decrease of 1.33%; profit attributable to shareholders of RMB 472 million, a year-on-year decrease of 11.4%; basic earnings per share of 12.54 cents. No final dividend is declared.

During the reporting period, the sales of products in the central nervous system treatment field decreased by 4.8%, reaching RMB 1.613 billion. Sales in the oncology treatment field decreased by 1.8%, reaching RMB 2.085 billion. Sales in the cardiovascular system treatment field decreased by 1.6%, reaching RMB 1.660 billion. Sales in the metabolic treatment field decreased by 13.7%, reaching RMB 389 million

### Related Stocks

- [02186.HK - LUYE PHARMA](https://longbridge.com/en/quote/02186.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Maine CDC reports 4 additional cases of measles have been confirmed in Maine | Maine CDC reports 4 additional cases of measles have been confirmed in Maine | [Link](https://longbridge.com/en/news/276164223.md) |
| 11:53 ETVerana Health Introduces Industry First End-to-End Urologic-Oncology Datasets to Support Research | Verana Health has launched new urologic-oncology datasets aimed at enhancing research for bladder and prostate cancer tr | [Link](https://longbridge.com/en/news/276359690.md) |
| 08:46 ETCenter for Asbestos Related Disease, Inc. (CARD) Invites Community Members to Attend an Open House and Ribbon Cutting Celebration | The Center for Asbestos Related Disease, Inc. (CARD) is hosting an Open House and Ribbon Cutting celebration on February | [Link](https://longbridge.com/en/news/276235741.md) |
| 10:39 ETThe EveryLife Foundation for Rare Diseases Marks 15th Annual Rare Disease Week on Capitol Hill | The EveryLife Foundation for Rare Diseases will host its 15th Annual Rare Disease Week on Capitol Hill from February 24- | [Link](https://longbridge.com/en/news/276247135.md) |
| How Richardson Dentists Help Patients Protect Their Smiles as They Age | Richardson dentists focus on helping patients maintain their smiles as they age, addressing various oral health needs fr | [Link](https://longbridge.com/en/news/276462384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.